This inventor holds 5 USPTO granted patents and 7 published patent applications and 2 EPO patents. Top assignee: Morphic Therapeutic, Inc.. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: Andrea Bortolato: Innovator in Integrin Inhibition
Introduction
Andrea Bortolato is a notable inventor based in Metuchen, NJ (US). He has made significant contributions to the field of integrin inhibition, holding a total of 5 patents. His work focuses on developing small molecule inhibitors that target specific integrins, which are crucial in various diseases and conditions.
Latest Patents
Bortolato's latest patents include innovative methods for inhibiting αvβ6 integrin. These patents disclose small molecule inhibitors of αvβ6 integrin and outline methods for using them to treat a range of diseases and conditions. His research is pivotal in advancing therapeutic options for patients suffering from conditions related to integrin activity.
Career Highlights
Andrea Bortolato is currently associated with Morphic Therapeutics, Inc., a company dedicated to developing transformative medicines. His expertise in integrin biology and small molecule drug design has positioned him as a key player in the pharmaceutical industry.
Collaborations
Bortolato has collaborated with esteemed colleagues, including James E. Dowling and Dawn M. Troast. These partnerships enhance the innovative potential of his research and contribute to the advancement of therapeutic strategies.
Conclusion
Andrea Bortolato's work in integrin inhibition exemplifies the impact of innovative research in medicine. His patents and collaborations reflect a commitment to improving treatment options for various diseases.